Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

The study is comprised of 2 sequential parts: Part A (Dose Escalation of VS-6063) and Part B
(Expansion).

In Part A (Dose Escalation), approximately 18 subjects will receive avelumab IV treatment in
28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15) and oral defactinib
twice-daily (BID) continuously starting on Day 1 of Cycle 1. Subject enrollment will proceed
according to a standard 3+3 design. In the absence of dose-limiting toxicity (DLT), each
subject will receive the study drug regimen for a minimum of 28 days (Cycle 1) and may
continue to receive additional cycles of study treatment until disease progression has been
documented or unacceptable toxicity or other treatment discontinuation criteria have been
met. All subjects in a cohort must have completed at least 1 cycle of dosing before dose
escalation involving new subjects entered into the next dose cohort can occur. Based on the
safety and PK data obtained in the dose escalation portion of the study, the RP2D of the
combination will be determined.

In Part B (Expansion), approximately 80 subjects will be enrolled and will receive avelumab
IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15) and oral
defactinib at the RP2D dose continuously starting on Day 1 of Cycle 1.

Inclusion Criteria:

1. Able to provide signed and dated informed consent before initiation of any study
procedures.

2. Willing and able to participate in the trial and comply with all trial requirements.

3. Female subject aged ≥ 18 years.

4. Histologically or cytologically-confirmed recurrent or resistant (progression within 6
months following the last administered platinum based therapy or progression after
subsequent therapy in previously relapsed subjects), stage III-IV epithelial ovarian,
fallopian tube or peritoneal cancer subjects (according to American Joint Committee on
Cancer/Union for International Cancer Control TNM and International Federation of
Gynecology and Obstetrics Staging System, 7th edition) whose disease has progressed
following adjuvant therapy or therapy for metastatic disease.

5. Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST
1.1.

6. Confirmed availability of archived FFPE tumor tissue block, or a minimum of 15 slides.
If archived FFPE tissue is not available, then fresh tumor sample may be obtained in
accordance with local institutional practice for tumor biopsies.

7. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1, measured within
72 hours before the start of treatment.

8. Predicted life expectancy of ≥ 3 months.

9. Adequate renal function with normal serum creatinine, or if creatinine above or below
institutional normal range, a calculated glomerular filtration rate of ≥ 50
mL/min/1.73m2 (e.g., as calculated by the Cockcroft Gault formula) using actual body
weight; if subject has body mass index > 30 kg/m2, lean body weight must be used.

10. Adequate hepatic function (total bilirubin ≤ 1.5 × upper limit of normal [ULN] for the
institution; aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN.

11. Adequate bone marrow function (hemoglobin [Hb] ≥ 9.0 g/dL [subjects may be transfused
to Hb ≥ 9.0 g/dL]; platelets ≥ 100 × 109cells/L; absolute neutrophil count [ANC] ≥ 1.5
× 109 cells/L without the use of hematopoietic growth factors).

12. Corrected QT interval (QTc) < 470 msec (as calculated by the Fridericia correction
formula [QTcF]).

13. Negative pregnancy test within 72 hours prior to the first dose of protocol therapy
for women of childbearing potential. Must be willing to use effective contraception
for 30 days before the first study drug administration, for the duration of trial
participation and at least for 60 days after stopping trial participation. Should a
woman become pregnant or suspect she is pregnant while she or her partner is
participating in this trial, the treating physician must be informed immediately.

Exclusion Criteria:

1. Concurrent anticancer treatment, major surgery or use of any investigational drug
within 28 days or 5 half-lives, whichever is shorter, before the start of trial
treatment; palliative radiation therapy is allowed if > 21 days before planned first
dose of study drugs and any toxicity is ≤ Grade 1.

2. Concurrent systemic therapy with immunosuppressive agents; use of hormonal agents
within 7 days before the start of trial treatment. Note: subjects receiving
bisphosphonate or denosumab are eligible provided treatment was initiated at least 14
days before the first dose of avelumab. Subjects receiving immunosuppressive agents
(such as corticosteroids) for any reason should be tapered off these drugs before
initiation of the study treatment (with the exception of subjects with adrenal
insufficiency, who may continue corticosteroids at physiologic replacement dose,
equivalent to ≤ 10 mg prednisone daily). Steroids with no or minimal systemic effect
(topical, inhalation) are allowed.

3. Prior treatment with a drug of the focal adhesion kinase (FAK) inhibitor class.

4. Prior therapy with specific antibody/drug targeting immune or coregulatory or
costimulatory proteins (such as checkpoints e.g., PD-1 or PD L1, 4-1BB, OX40 or CTLA-4
antibodies).

5. Receipt of any organ transplantation including autologous or allogeneic stem-cell
transplantation.

6. Uncontrolled brain metastases (Stable brain metastases either treated or being treated
with a stable dose of anticonvulsants, with no dose change within 28 days before
enrollment, will be allowed.).

7. Women who are pregnant or breastfeeding.

8. Any evidence of serious active infections; any infections being treated must complete
antibiotic therapy at least 7 days before planned first dose.

9. Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo,
psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are
eligible).

10. Current acute or chronic colitis, inflammatory bowel disease, pneumonitis or pulmonary
fibrosis.

11. Known severe hypersensitivity reactions to monoclonal antibodies; any history of
anaphylaxis or uncontrolled asthma.

12. Uncontrolled or severe cardiovascular disease, including myocardial infarct or
unstable angina within 6 months before study treatment, New York Heart Association
Class II or greater congestive heart failure, serious arrhythmias requiring medication
for treatment, clinically significant pericardial disease or cardiac amyloidosis.

13. Known history of stroke or cerebrovascular accident within 6 months before enrollment.

14. Known infection with human immunodeficiency virus (HIV) or acquired immune deficiency
syndrome (AIDS) (testing not required).

15. Active hepatitis B or C (testing required).

16. Known history of Gilbert's Syndrome.

17. Other uncontrolled or poorly controlled intercurrent illness (e.g., involving the
renal, hepatic, neurologic, dermatologic, pulmonary, endocrine systems) or psychiatric
illness/social situations that would limit compliance with study requirements, place
the subject at undue risk or confound interpretation of safety or other data.

18. Gastrointestinal (GI) condition that could interfere with the swallowing or absorption
of defactinib.

19. History of upper GI bleeding, ulceration or perforation within 6 months before the
first dose of defactinib.

20. Vaccination within 4 weeks of the first dose of avelumab and while on trials is
prohibited except for administration of inactivated vaccines.

21. Previous malignant disease other than the target malignancy to be investigated in this
trial within the last 3 years, with the exception of basal or squamous cell carcinoma
of the skin or cervical carcinoma in situ. Any prior cancer must not be getting active
treatment and must be in continuous complete remission for at least 3 years.

22. Persisting toxicity related to prior therapy > Grade 1 National Cancer Institute
Common Terminology Criteria for Adverse Events, version 4.03 (NCI-CTCAE v4.03);
however, sensory neuropathy ≤ Grade 2 is acceptable.